H.C. Wainwright Reaffirms Buy on argenx (ARGX), Highlights Pipeline Progress

argenx SE (NASDAQ:ARGX) is one of the high growth stocks outside tech analysts are bullish on. H.C. Wainwright analyst Douglas Tsao has reaffirmed a Buy rating on argenx SE (NASDAQ:ARGX) as of July 1, citing strong progress in the company’s neuromuscular treatment pipeline. With a current market price of $598.40 and Bank of America’s price target of $804, the stock offers a potential upside of about 34.3%.

ChatGPT said: H.C. Wainwright Reaffirms Buy on argenx (ARGX), Highlights Pipeline Progress

A lab setting filled with scientific equipment and researchers in lab coats working together to develop new therapies for autoimmune diseases.

The bullish stance is driven by the advancement of ARGX-119, now entering a registrational trial for congenital myasthenic syndromes (CMS). This marks the company’s third molecule to reach late-stage clinical development. Positive Phase 1b results showed promising safety and consistent improvements in patient outcomes, which boosted investor confidence.

ARGX-119 also highlights the growing potential of argenx’s SIMPLE Antibody platform, a proprietary technology for developing precise antibody-based therapies. The ongoing natural history study in CMS is expected to add valuable, real-world insight that could support regulatory submissions.

The company is also conducting a Phase 2a study of ARGX-119 in amyotrophic lateral sclerosis (ALS), a move that could broaden its future treatment offerings. If successful, ARGX-119 could become the first therapy approved for DOK7-CMS, a very rare form of neuromuscular disease.

argenx develops antibody-based therapies for rare autoimmune and neuromuscular disorders.

READ NEXT: 10 Most Profitable Consumer Stocks to Buy Now and 10 Best High-Margin Pharma Stocks to Buy Now.

Disclosure: None.